Candel Therapeutics to Showcase NSCLC and Glioblastoma Data at SITC 2026
Event summary
- Candel Therapeutics will present data on aglatimagene besadenovec for NSCLC and linoserpaturev for recurrent glioblastoma at the SITC 2026 Annual Meeting.
- Poster presentations will cover multi-omics analyses of aglatimagene besadenovec and VEGF blockade combinations with linoserpaturev.
- Presentations scheduled for November 6 and 7, 2026, at the Phoenix Convention Center.
- Aglatimagene besadenovec has been dosed in over 1,000 patients with a favorable tolerability profile.
- Linoserpaturev has received Fast Track and Orphan Drug Designations from the FDA for recurrent high-grade glioma.
The big picture
Candel Therapeutics' presentations at SITC 2026 highlight its focus on advancing multimodal immunotherapies for difficult-to-treat cancers. The company's aglatimagene besadenovec and linoserpaturev programs are positioned to leverage immune activation and oncolysis, respectively, addressing significant unmet needs in NSCLC and glioblastoma. The strategic emphasis on combination therapies and regulatory designations underscores Candel's approach to differentiating its pipeline in a crowded oncology market.
What we're watching
- Clinical Efficacy
- How the multi-omics data from aglatimagene besadenovec will impact its development trajectory in NSCLC.
- Regulatory Pathway
- Whether the combination of linoserpaturev with VEGF blockade can accelerate its approval for recurrent glioblastoma.
- Market Positioning
- The pace at which Candel Therapeutics can differentiate its multimodal immunotherapies in a competitive oncology landscape.
Related topics